

i-STAT CG4+ Cartridge

Intended for use with the i-STAT 1 Analyzer (REF 04P75-01 & 03P75-06)

NAME

i-STAT CG4+ Cartridge – REF 03P85-25



INTENDED USE

The i-STAT CG4+ cartridge with the i-STAT 1 System is intended for use in the *in vitro* quantification of pH, oxygen partial pressure, carbon dioxide partial pressure, and lactate in arterial, venous or capillary whole blood.

Analyte	Intended Use
pH	pH, PO_2 , and PCO_2 measurements are used in the diagnosis, monitoring, and treatment of respiratory disturbances and metabolic and respiratory-based acid-base disturbances.
Oxygen Partial Pressure (PO_2)	
Carbon Dioxide Partial Pressure (PCO_2)	Bicarbonate is used in the diagnosis and treatment of numerous potentially serious disorders associated with changes in body acid-base balance.
Lactate	The i-STAT lactate test is useful for (1) the diagnosis and treatment of lactic acidosis in conjunction with measurements of blood acid/base status, (2) monitoring tissue hypoxia and strenuous physical exertion, and (3) diagnosis of hyperlactatemia.

SUMMARY AND EXPLANATION / CLINICAL SIGNIFICANCE

Measured:

pH

pH is an index of the acidity or alkalinity of the blood with an arterial pH of <7.35 indicating an acidemia and >7.45 alkalemia.¹

Oxygen Partial Pressure (PO_2)

PO_2 (partial pressure of oxygen) is a measurement of the tension or pressure of oxygen dissolved in blood. Some causes for decreased values of PO_2 include decreased pulmonary ventilation (e.g., airway obstruction or trauma to the brain), impaired gas exchange between alveolar air and pulmonary capillary blood (e.g., bronchitis, emphysema, or pulmonary edema), and alteration in the flow of blood within the heart or lungs (e.g., congenital defects in the heart or shunting of venous blood into the arterial system without oxygenation in the lungs).

Carbon Dioxide Partial Pressure (PCO_2)

PCO_2 along with pH is used to assess acid-base balance. PCO_2 (partial pressure of carbon dioxide), the respiratory component of acid-base balance, is a measure of the tension or pressure of carbon dioxide dissolved in the blood. PCO_2 represents the balance between cellular production of CO_2 and ventilatory removal of CO_2 and a change in PCO_2 indicates an alteration in this balance. Causes of primary respiratory acidosis (increase in PCO_2) are airway obstruction, sedatives and anesthetics, respiratory distress syndrome, and chronic obstructive pulmonary disease. Causes of primary respiratory alkalosis (decreased PCO_2) are hypoxia (resulting in hyperventilation) due to chronic heart failure, edema and neurologic disorders, and mechanical hyperventilation.

Lactate (Lac)

Elevated levels of lactate are mainly found in conditions of hypoxia such as shock, hypovolemia, and left ventricular failure; in conditions associated with diseases such as diabetes mellitus, neoplasia, and liver disease; and in conditions associated with drugs or toxins such as ethanol, methanol, or salicylates.²

Hyperlactatemia is an indicator commonly used to detect tissue hypoperfusion, particularly in the case of sepsis,^{3 4 5} but also in trauma^{6 7 8} and surgical^{9 10 11} settings.

TEST PRINCIPLE

The i-STAT System uses direct (undiluted) electrochemical methods. Values obtained by direct methods may differ from those obtained by indirect (diluted) methods.¹²

Measured:

pH

pH is measured by direct potentiometry. In the calculation of results for pH, concentration is related to potential through the Nernst equation.

PO₂


PO₂ is measured amperometrically. The oxygen sensor is similar to a conventional Clark electrode. Oxygen permeates through a gas permeable membrane from the blood sample into an internal electrolyte solution where it is reduced at the cathode. The oxygen reduction current is proportional to the dissolved oxygen concentration.

PCO₂

PCO₂ is measured by direct potentiometry. In the calculation of results for PCO₂, concentration is related to potential through the Nernst equation.

Lactate (Lac)

Lactate is measured amperometrically. The enzyme lactate oxidase, immobilized in the lactate biosensor, selectively converts lactate to pyruvate and hydrogen peroxide (H₂O₂). The liberated hydrogen peroxide is oxidized at a platinum electrode to produce a current which is proportional to the sample lactate concentration.



Temperature "Correction" Algorithm

pH, PO₂, and PCO₂ are temperature-dependent quantities and are measured at 37°C. The pH, PO₂, and PCO₂ readings at a body temperature other than 37°C can be 'corrected' by entering the patient's temperature on the chart page of the analyzer. In this case, blood gas results will be displayed at both 37°C and the patient's temperature.

pH, PO₂, and PCO₂ at the patient's temperature (T_p) are calculated as follows :¹³

$$pH(T_p) = pH - 0.0147(T_p - 37) + 0.0065(7.4 - pH)(T_p - 37)$$

$$PO_2(T_p) = PO_2 \times 10^{\frac{5.49 \times 10^{-11} PO_2^{3.88} + 0.071}{9.72 \times 10^{-9} PO_2^{3.88} + 2.30} (T_p - 37)}$$

$$PCO_2(T_p) = PCO_2 \times 10^{0.019(T_p - 37)}$$

Calculated:

HCO₃, TCO₂, and BE

- HCO₃ (bicarbonate), the most abundant buffer in the blood plasma, is an indicator of the buffering capacity of blood. Regulated primarily by the kidneys, HCO₃ is the metabolic component of acid-base balance.
- TCO₂ is a measure of carbon dioxide which exists in several states: CO₂ in physical solution or loosely bound to proteins, bicarbonate (HCO₃) or carbonate (CO₃) anions, and carbonic acid (H₂CO₃). Measurement of TCO₂ as part of an electrolyte profile is useful chiefly to evaluate HCO₃ concentration. TCO₂ and HCO₃ are useful in the assessment of acid-base imbalance (along with pH and PCO₂) and electrolyte imbalance.
- The calculated TCO₂ provided by the i-STAT System is determined from the measured and reported values of pH and PCO₂ according to a simplified and standardized form of the Henderson-Hasselbalch equation.¹³
- This calculated TCO₂ measurement is metrologically traceable to the i-STAT pH and PCO₂ measurements, which are in turn traceable to primary standard reference materials for pH and PCO₂. Like all calculated parameters reported by the i-STAT System, the user can independently determine TCO₂ values from the reported pH and PCO₂ measurements using a combination of the equation for HCO₃ and the equation for TCO₂ below.
- Base excess of the extracellular fluid (ECF) or standard base excess is defined as the concentration of titratable base minus the concentration of titratable acid when titrating the average ECF (plasma plus interstitial fluid) to an arterial plasma pH of 7.40 at PCO₂ of 40 mmHg at 37 °C. Excess concentration of base in the average ECF remains virtually constant during acute changes in the PCO₂ and reflects only the non-respiratory component of pH-disturbances.

When a cartridge includes sensors for both pH and PCO₂, bicarbonate (HCO₃), total carbon dioxide (TCO₂) and base excess (BE) are calculated.¹³

$$\log HCO_3 = pH + \log PCO_2 - 7.608$$

$$TCO_2 = HCO_3 + 0.03PCO_2$$

$$BE_{ecf} = HCO_3 - 24.8 + 16.2(pH - 7.4)$$

$$BE_b = (1 - 0.014 \cdot Hb) * [HCO_3 - 24.8 + (1.43 * Hb + 7.7) * (pH - 7.4)]$$

sO₂

- sO₂ (oxygen saturation) is the amount of oxyhemoglobin expressed as a fraction of the total amount of hemoglobin able to bind oxygen (oxyhemoglobin plus deoxyhemoglobin).
- sO₂ is calculated from measured PO₂ and pH and from HCO₃ calculated from measured PCO₂ and pH. However, this calculation assumes normal affinity of oxygen for hemoglobin. It does not take into account erythrocyte diphosphoglycerate (2,3-DPG) concentrations which affect the oxygen dissociation curve. The calculation also does not take into account the effects of fetal hemoglobin or dysfunctional hemoglobins (carboxy-, met-, and sulfhemoglobin). Clinically significant errors can result from incorporation of such an estimated sO₂ value for oxygen saturation in further calculations, such as shunt fraction, or by assuming the value obtained is equivalent to fractional oxyhemoglobin.

$$sO_2 = 100 \cdot \frac{(X^3 + 150X)}{X^3 + 150X + 23400}$$

where $X = PO_2 \cdot 10^{(0.48[pH-7.4]-0.0013[HCO_3^- - 25])}$

See below for information on factors affecting results. Certain substances, such as drugs, may affect analyte levels in vivo. ¹⁴ If results appear inconsistent with the clinical assessment, the patient sample should be retested using another cartridge.

REAGENTS

Contents

Each i-STAT cartridge contains one reference electrode, sensors for the measurement of specific analytes, and a buffered aqueous calibrant solution that contains known concentrations of analytes and preservatives. A list of reactive ingredients relevant for the i-STAT CG4+ cartridge is indicated below:

Sensor	Reactive Ingredient	Biological Source	Minimum Quantity
pH	Hydrogen Ion (H ⁺)	N/A	6.66 pH
PCO ₂	Carbon Dioxide (CO ₂)	N/A	25.2 mmHg
Lactate	Lactate	N/A	1.8 mmol/L
	Lactate Oxidase	<i>Aerococcus viridans</i>	0.001 IU

Warnings and Precautions

- For *in vitro* diagnostic use.
- Cartridges are intended for single-use only. Do not reuse.
- Refer to the i-STAT 1 System Manual for all warnings and precautions.

Storage Conditions

- Refrigerated at 2-8°C (35-46°F) until expiration date.
- Room Temperature at 18-30°C (64-86°F). Refer to the cartridge box for shelf life.

INSTRUMENTS

The i-STAT CG4+ cartridge is intended for use with the i-STAT 1 analyzer REF 04P75-01 (Model 300-G) and REF 03P75-06 (Model 300W).

SPECIMEN COLLECTION AND PREPARATION FOR ANALYSIS

Specimen Types

Arterial, venous or capillary whole blood.

Sample Volume: 95 µL

Blood Collection Options and Test Timing (time from collection to cartridge fill)

Analyte	Syringes	Test Timing	Evacuated Tubes	Test Timing	Capillary	Test Timing
Lactate	Without anticoagulant	Immediately	Without anticoagulant	Immediately	With balanced heparin anticoagulant	Immediately

Analyte	Syringes	Test Timing	Evacuated Tubes	Test Timing	Capillary	Test Timing
	With balanced heparin anticoagulant or lithium heparin anticoagulant (syringe must be filled per manufacturer's recommendation) • Mix thoroughly before filling cartridge.		With lithium heparin anticoagulant (tubes must be filled per manufacturer's recommendation) • Mix thoroughly before filling cartridge.		With lithium heparin if labeled for the measurement of electrolytes	
pH PCO ₂ PO ₂	Without anticoagulant	3 minutes	Without anticoagulant	3 minutes	With balanced heparin anticoagulant	3 minutes
	With balanced heparin anticoagulant or lithium heparin anticoagulant (syringe must be filled per manufacturer's recommendation) • Maintain anaerobic conditions. • Remix thoroughly before filling cartridge.	10 minutes	With lithium heparin anticoagulant (tubes must be filled per manufacturer's recommendation) • Maintain anaerobic conditions. • Remix thoroughly before filling cartridge	10 minutes	With lithium heparin if labeled for the measurement of electrolytes	3 minutes

PROCEDURE FOR CARTRIDGE TESTING

Each cartridge is sealed in a foil pouch for protection during storage--do not use if pouch has been punctured.

- A cartridge should not be removed from its protective pouch until it is at room temperature (18-30 °C or 64-86 °F). For best results, the cartridge and analyzer should be at room temperature.
- Since condensation on a cold cartridge may prevent proper contact with the analyzer, allow refrigerated cartridges to equilibrate at room temperature for 5 minutes for a single cartridge and 1 hour for an entire box before use.
- Use a cartridge immediately after removing it from its protective pouch. Prolonged exposure may cause a cartridge to fail a Quality Check.
- Do not return unopened, previously refrigerated cartridges to the refrigerator.
- Cartridges may be stored at room temperature for the time frame indicated on the cartridge box.

Filling and Sealing the Cartridge (after cartridge has been equilibrated and blood sample has been collected)

1. Place the cartridge on a flat surface.

-
2. Mix the sample thoroughly. Invert a lithium heparin blood collection tube at least 10 times. If sample was collected into a syringe, invert syringe for 5 seconds then roll the syringe between the palms (hands parallel to the ground) for 5 seconds, flip and roll for an additional 5 seconds. The blood in the hub of the syringe will not mix, therefore expelling 2 drops before filling a cartridge is desired. Note that it may be difficult to properly mix a sample in a 1.0 mL syringe.
 3. Fill the cartridge immediately after mixing. Direct the hub of syringe or tip of the transfer device (capillary tube, pipette or dispensing tip) into the sample well of the cartridge.
 4. Slowly dispense sample into the sample well until the sample reaches the fill mark indicated on the cartridge. Cartridge is properly filled when the sample reaches the 'fill to' mark and a small amount of sample is in the sample well. The sample should be continuous, no bubbles or breaks (see System Manual for details).
 5. Fold the snap closure of the cartridge over the sample well.

Performing Patient Analysis

1. Press the power button to turn on the handheld.
2. Press 2 for *i-STAT Cartridge*.
3. Follow the handheld prompts.
4. Scan the lot number on the cartridge pouch.
5. Continue normal procedures for preparing the sample, and filling and sealing the cartridge.
6. Push the sealed cartridge into the handheld port until it clicks into place. Wait for the test to complete.
7. Review the results.

For additional information for cartridge testing, refer to the i-STAT 1 System Manual located at www.pointofcare.abbott.

Analysis Time

Approximately 130–200 seconds

Quality Control

The i-STAT quality control regimen has four aspects, resting on the foundation of a system design, which reduces the opportunity for the type of error which traditional quality control regimens are designed to detect:

1. A series of automated, on-line quality measurements that monitor the sensors, fluidics and instrumentation each time a test is performed.
2. A series of automated, on-line procedural checks monitors the user each time a test is performed.
3. Liquid materials are available to be used to verify the performance of a batch of cartridges when they are first received or when storage conditions are in question. The performance of this procedure is not a manufacturer's system instruction.
4. Traditional quality control measurements verify the instrumentation using an independent device, which simulates the characteristics of the electrochemical sensors in a way which stresses the performance characteristics of the instrumentation.

For additional information on Quality Control, refer to the i-STAT 1 System Manual located at www.pointofcare.abbott.

Calibration Verification

Calibration Verification is a procedure intended to verify the accuracy of results over the entire measurement range of a test. The performance of this procedure is not a manufacturer's system instruction. However, it may be required by regulatory or accreditation bodies. While the Calibration Verification Set contains five levels, verification of the measurement range could be accomplished using the lowest, highest and mid-levels.

EXPECTED VALUES

TEST	UNITS *	REPORTABLE RANGE	REFERENCE RANGE	
			(arterial)	(venous)
MEASURED				
pH		6.50 - 8.20	7.35 - 7.45 ¹⁵	7.31 - 7.41**
PO ₂	mmHg	5 - 800	80 - 105 ^{16***}	
	kPa	0.7 – 106.6	10.7 - 14.0 ^{16***}	
PCO ₂	mmHg	5 - 130	35 - 45 ¹⁵	41 - 51
	kPa	0.67 – 17.33	4.67 - 6.00	5.47 - 6.80
Lactate/Lac	mmol/L	0.30 - 20.00	0.36 - 1.25 ^{2****}	0.90 - 1.70 ^{2****}
	mg/dL	2.7 – 180.2	3.2 - 11.3 ^{2****}	8.1 - 15.3 ^{2****}
CALCULATED				
Bicarbonate/ HCO ₃	mmol/L (mEq/L)	1.0 – 85.0	22 – 26**	23 – 28**
TCO ₂	mmol/L (mEq/L)	5 - 50	23 - 27	24 - 29
Base Excess/BE	mmol/L (mEq/L)	(-30) – (+30)	(-2) – (+3) ¹⁵	(-2) – (+3) ¹⁵
sO ₂	%	0-100	95 - 98	

* The i-STAT System can be configured with the preferred units. Not applicable for pH test.

** Calculated from Siggard-Andersen nomogram. ¹

*** The reference ranges shown are for a healthy population. Interpretation of blood gas measurements depend on the underlying condition (e.g., patient temperature, ventilation, posture and circulatory status).

**** The i-STAT reference ranges for whole blood listed above are similar to reference ranges derived from serum or plasma measurements with standard laboratory methods.

Unit Conversion

- **PO₂ and PCO₂:** To convert **PO₂** and **PCO₂** results from mmHg to kPa, multiple the mmHg value by 0.133.
- **Lactate/Lac:** To convert a Lactate result from mmol/L to mg/dL, multiply the mmol/L value by 9.01.

The reference ranges programmed into the analyzer and shown above are intended to be used as guides for the interpretation of results. Since reference ranges may vary with demographic factors such as age, gender and heritage, it is recommended that reference ranges be determined for the population being tested.

METROLOGICAL TRACEABILITY

The measured analytes in the i-STAT CG4+ cartridge are traceable to the following reference materials or methods. The i-STAT System controls and calibration verification materials are validated for use only with the i-STAT System and assigned values may not be commutable with other methods.

pH

The i-STAT System test for pH measures the hydrogen ion amount-of-substance concentration in the plasma fraction of arterial, venous or capillary whole blood (expressed as the negative logarithm of the relative molal hydrogen ion activity) for *in vitro* diagnostic use. pH values assigned to the i-STAT System controls and calibration verification materials are traceable to the U.S. National Institute of Standards and Technology (NIST) standard reference materials SRMs 186-I, 186-II, 185, and 187.

PO₂

The i-STAT System test for oxygen partial pressure measures oxygen partial pressure in arterial, venous or capillary whole blood (dimension kPa) for *in vitro* diagnostic use. **PO₂** values assigned to the i-STAT System controls and calibration verification materials are traceable to U.S. National Institute of Standards and Technology (NIST) standard reference materials via commercially available certified specialty medical gas standards.

PCO₂

The i-STAT System test for carbon dioxide partial pressure measures carbon dioxide partial pressure in arterial, venous or capillary whole blood (dimension kPa) for *in vitro* diagnostic use. **PCO₂** values assigned to the i-STAT System controls and calibration verification materials are traceable to U.S. National Institute of Standards and Technology (NIST) standard reference materials via commercially available certified specialty medical gas standards.

Lactate/Lac

The i-STAT System test for lactate measures L-lactate amount-of-substance concentration in the plasma fraction of arterial, venous or capillary whole blood (dimension mmol L⁻¹) for *in vitro* diagnostic use. Presently, no international conventional reference measurement procedure or international conventional calibrator for lactate is available. Lactate values assigned to the i-STAT System controls and calibration verification materials are traceable to i-STAT System working calibrator prepared from sodium L-lactate (Sigma-Aldrich Fluka, >99 % purity).

Additional information regarding metrological traceability is available from Abbott Point of Care Inc.

PERFORMANCE CHARACTERISTICS

The typical performance data summarized below was collected in health care facilities by health care professionals trained in the use of the i-STAT System and comparative methods.

Precision

Precision data for the i-STAT pH, **PO₂**, **PCO₂**, and Lactate tests as part of the i-STAT 1 System were collected in multiple sites as follows: Duplicates of each control fluid were tested in the morning and in the afternoon on five days for a total of 20 replicates. The averaged statistics are presented below.

Test	Units	Aqueous Control	Mean	SD (Standard Deviation)	CV (%) [Coefficient of Variation (%)]
pH		Level 1	7.165	0.005	0.08
		Level 3	7.656	0.003	0.04
PO₂	mmHg	Level 1	65.1	3.12	4.79
		Level 3	146.5	6.00	4.10
PCO₂	mmHg	Level 1	63.8	1.57	2.5
		Level 3	19.6	0.40	2.0
Lactate*	mmol/L	Level 1	6.35	0.08	1.21
		Level 3	0.81	0.03	3.27

* Precision data were collected using CLSI guideline EP5-A. ¹⁷ Duplicates of each level of control were tested on three lots of cartridges over 20 days for a total of 120 replicates.

Method Comparison

Method comparison data were collected using CLSI guideline EP9-A. ¹⁸

Deming regression analysis ¹⁹ was performed on the first replicate of each sample. In the method comparison table, n is the number of specimens in the data set, Sxx and Syy refer to estimates of imprecision based on the duplicates of the comparative and the i-STAT methods respectively, Sy.x is the standard error of the estimate, and r is the correlation coefficient.*

Method comparisons will vary from site to site due to differences in sample handling, comparative method calibration and other site-specific variables.

* The usual warning relating to the use of regression analysis is summarized here as a reminder. For any analyte, "if the data is collected over a narrow range, the estimate of the regression parameters are relatively imprecise and may be biased. Therefore, predictions made from these estimates may be invalid".¹⁹ The correlation coefficient, r, can be used as a guide to assess the adequacy of the comparative method range in overcoming this problem. As a guide, the range of data can be considered adequate if $r > 0.975$.

pH	Radiometer IL BGE		Nova STAT Profile 5	Radiometer ABL500	
Venous blood samples were collected in evacuated tubes and arterial samples were collected in blood gas syringes with lithium heparin anticoagulant. All samples were analyzed in duplicate on the i-STAT System and on the comparative methods within 10 minutes of each other. Arterial blood samples were collected from hospital patients in 3 mL blood gas syringes and were analyzed in duplicate on the i-STAT System and the comparative method within 5 minutes of each other.	n	62	47	45	
	Sxx	0.005	0.011	0.006	0.004
	Syy	0.009	0.008	0.008	0.008
	Slope	0.974	1.065	1.058	1.0265
	Int't	0.196	-0.492	-0.436	-0.1857
	Sy.x	0.012	0.008	0.010	0.0136
	Xmin	7.210	7.050	7.050	----
	Xmax	7.530	7.570	7.570	----
	r	0.985	0.990	0.9920	0.986
Oxygen Partial Pressure/ PO ₂ (mmHg)	Radiometer ABL500		Radiometer ABL700	Bayer 845	
Arterial blood samples were collected from hospital patients in 3 cc blood gas syringes and were analyzed in duplicate on the i-STAT System and the comparative method within 5 minutes of each other.	n	45	29	30	
	Sxx	3.70	2.04	3.03	
	Syy	2.78	2.64	3.28	
	Slope	1.023	0.962	1.033	
	Int't	-2.6	1.2	-2.9	
	Sy.x	2.52	3.53	3.44	
	Xmin	----	39	31	
	Xmax	----	163	185	
	r	0.996	0.990	0.996	
Carbon Dioxide Partial Pressure/ PCO ₂ (mmHg)	IL BGE		Radiometer ABL500		
Venous blood samples were collected in blood gas syringes. All samples were analyzed in duplicate on the i-STAT System and on the comparative methods within 10 minutes of each other. Arterial blood samples were collected from hospital patients in 3 cc blood gas syringes and were analyzed in duplicate on the i-STAT System and the comparative method within 5 minutes of each other.	n	62	29		
	Sxx	0.69	0.74		
	Syy	1.24	0.53		
	Slope	1.003	1.016		
	Int't	-0.8	1.1		
	Sy.x	1.65	0.32		
	Xmin	30.4	28		
	Xmax	99.0	91		
	r	0.989	0.999		
Lactate/Lac (mmol/L)	Radiometer ABL 725 (whole blood vs. whole blood)		Hitachi 917 (i-STAT whole blood vs. Hitachi plasma)		
Venous blood samples, collected in sodium heparin Vacutainer® tubes, and arterial blood samples, collected in blood gas syringes, were analyzed in duplicate on the i-STAT System. In the plasma study, a portion of each specimen was centrifuged, and the separated plasma was analyzed on the comparative method.	n	47	47		
	Sxx	0.123	0.084		
	Syy	0.136	0.079		
	Slope	1.02	1.06		
	Int't	0.12	-0.32		
	Sy.x	0.18	0.17		
	Xmin	0.80	1.77		
	Xmax	14.20	14.24		
	r	0.998	0.997		

FACTORS AFFECTING RESULTS

The following substances were evaluated in plasma for relevant analytes at the test concentrations recommended in CLSI guideline EP7-A2 ²⁰ unless otherwise noted. For those identified as an interferant the interference is described.

Substance	Test Concentration (mmol/L)	Analyte	Interference (Yes/No)	Comment
Acetaldehyde	0.045 ²¹	Lactate	No	
Acetaminophen	1.32	Lactate	No	
Acetylcysteine	10.2	Lactate	No	
Ascorbate	0.34	Lactate	No	
Bromide	37.5	Lactate	Yes	Decreased results. Use another method.
Bromide (therapeutic)	2.5 ^{22 23 24}	Lactate	No	
Dopamine	0.006	Lactate	No	
Formaldehyde	0.133 ²¹	Lactate	No	
Glycolic Acid	10.0 ²¹	Lactate	Yes	Increased i-STAT lactate results. Use another method.
Hydroxyurea	0.92	Lactate	Yes	Increased i-STAT lactate results. Use another method.
β-Hydroxybuterate	6.0 ²⁵	Lactate	No	
Pyruvate	0.31	Lactate	No	
Salicylate	4.34	Lactate	No	
Uric Acid	1.4	Lactate	No	

The degree of interference at concentrations other than those reported above might not be predictable. It is possible that interfering substances other than those tested may be encountered.














- Relevant comments regarding interference of Bromide, Glycolic acid and Hydroxyurea are noted below:
 - Bromide has been tested at two levels: the CLSI recommended level and a therapeutic plasma concentration level of 2.5 mmol/L. The latter is the peak plasma concentration associated with halothane anesthesia, in which bromide is released. APOC has not identified a therapeutic condition that would lead to levels consistent with the CLSI recommended level. Bromide at a concentration of 37.5 mmol/L decreased i-STAT lactate results, while a therapeutic range of bromide (2.5 mmol/L) did not significantly interfere with i-STAT lactate results.
 - Glycolic acid is a product of ethylene glycol metabolism. Unexpected increased lactate concentrations caused by glycolic acid may be a clue to the possibility of ethylene glycol ingestion as the cause of an otherwise unknown high anion gap metabolic acidosis. ^{26 27} In a study of 35 patients who had ingested ethylene glycol, initial glycolic acid concentrations of 0 to 38 mmol/L corresponded to ethylene glycol levels of 0.97 – 130.6 mmol/L. ²⁷
 - Hydroxyurea has been shown to interfere with Lactate. Hydroxyurea is a DNA synthesis inhibitor used in the treatment of various forms of cancer, sickle cell anemia, and HIV infection. This drug is used to treat malignancies including melanoma, metastatic ovarian cancer, and chronic myelogenous leukemia. It is also used in the treatment of polycythemia vera, thrombocythemia, and psoriasis. At typical doses ranging from 500 mg to 2 g/day, concentrations of hydroxyurea in patients' blood may be sustained at approximately 100 to 500 μmol/L. Higher concentrations may be observed soon after dosing or at higher therapeutic doses.

OTHER FACTORS AFFECTING RESULTS

Factor	Analyte	Effect
Exposing the sample to air	PO_2	Exposure of the sample to air will cause an increase in PO_2 when values are below 150 mmHg and a decrease in PO_2 when values are above 150 mmHg (approximate PO_2 of room air).
	pH	Exposing the sample to air allows CO_2 to escape which causes PCO_2 to decrease and pH to increase and HCO_3 and TCO_2 to be underestimated.
	PCO_2	
	HCO_3	
	TCO_2	
Venous stasis	pH	Venous stasis (prolonged tourniquet application) and forearm exercise may decrease pH due to localized production of lactic acid.
Hemodilution	pH	Hemodilution of the plasma by more than 20% associated with priming cardiopulmonary bypass pumps, plasma volume expansion or other fluid administration therapies using certain solutions may cause clinically significant error on sodium, chloride, ionized calcium and pH results. These errors are associated with solutions that do not match the ionic characteristics of plasma. To minimize these errors when hemodiluting by more than 20%, use physiologically balanced multi-electrolyte solutions containing low-mobility anions (e.g., gluconate).
Cold temperature	PO_2	Do not ice samples before testing - PO_2 results may be falsely elevated in cold samples. Do not use a cold cartridge - PO_2 results may be falsely decreased if the cartridge is cold.
Sample collection	Lactate	Special collection procedures are necessary to prevent changes in lactate both during and after the blood is drawn. For steady state lactate concentrations, patients should be at rest for 2 hours and fasting. Venous samples should be obtained without the use of a tourniquet or immediately after the tourniquet is applied. Both venous and arterial samples may be collected into heparinized syringes.
Allowing blood to stand (without exposure to air)	pH	pH decreases on standing anaerobically at room temperature at a rate of 0.03 pH units per hour. ¹
	PO_2	Standing anaerobically at room temperature will decrease PO_2 at a rate of 2–6 mmHg per hour. ¹
	PCO_2	Standing anaerobically at room temperature will increase PCO_2 by approximately 4 mmHg per hour.
	HCO_3	Allowing blood to stand (without exposure to air) before testing allows PCO_2 to increase and pH to decrease, which will cause HCO_3 and TCO_2 to be over-estimated, due to metabolic processes.
	TCO_2	
	Lactate	Samples for lactate should be analyzed immediately on drawing as lactate increases by as much as 70% within 30 minutes at 25 °C as a result of glycolysis. ²
Under fill or partial draw	PCO_2	The use of partial draw tubes (evacuated tubes that are adjusted to draw less than the tube volume, e.g., a 5 mL tube with enough vacuum to draw only 3 mL) is not recommended due to the potential for decreased PCO_2 , HCO_3 and TCO_2 values. Underfilling blood collection tubes may also cause decreased PCO_2 , HCO_3 and TCO_2 results. Care must be taken to eliminate “bubbling” of the sample with a pipette when filling a cartridge to avoid the loss of CO_2 in the blood.
	HCO_3	
	TCO_2	
Method of calculation	sO_2	Calculated sO_2 values from a measured PO_2 and an assumed oxyhemoglobin dissociation curve may differ significantly from the direct measurement. ¹³
Clinical conditions	HCO_3	Causes of primary metabolic acidosis (decrease calculated HCO_3) are ketoacidosis, lactate acidosis (hypoxia), and diarrhea. Causes of primary metabolic alkalosis (increase calculated HCO_3) are vomiting and antacid treatment.
Propofol (Diprivan®) or thiopental sodium	PCO_2	The use of CG4+ cartridge is recommended, which is free from clinically significant interference at all relevant therapeutic doses.

Factor	Analyte	Effect
PO_2 sensitivity	PCO_2	<p>In patient samples where the PO_2 is > 100 mmHg above the normal range (80-105 mmHg), an increase in PCO_2 of approximately 1.5 mmHg (with a range of 0.9 to 2.0 mmHg) may be observed for every 100 mmHg increase in PO_2.</p> <p>For example, if an oxygenated patient has a measured PO_2 of 200 mmHg, and a normal PO_2 is 100 mmHg, the impact to the PCO_2 result may be increased by approximately 1.5 mmHg.</p>

KEY TO SYMBOLS

Symbol	Definition/Use
	2 months room temperature storage at 18-30°C
	Use by or expiration date. An expiration date expressed as YYYY-MM-DD means the last day the product can be used.
	Manufacturer's lot number or batch code. The lot number or batch will appear adjacent to this symbol.
	Sufficient for <n> tests
	Authorized representative for Regulatory Affairs in the European Community.
	Temperature limitations. The upper and lower limits for storage are adjacent to upper and lower arms.
	Catalog number, list number, or reference
	Do not reuse.
	Manufacturer
	Consult instructions for use or see System Manual for instructions.
	<i>In vitro</i> diagnostic medical device
	Compliance to the European directive on <i>in vitro</i> diagnostic devices (98/79/EC)
	For prescription use only.

Additional Information: To obtain additional product information and technical support, refer to the company website at www.pointofcare.abbott.

References

1. Pruden EL, Siggard-Andersen O, Tietz NW. Blood Gases and pH. In: C.A. Burtis and E.R. Ashwood, ed. *Tietz Textbook of Clinical Chemistry*. Second Edition ed. Philadelphia: W.B. Saunders Company; 1994.
2. Sacks DB. Carbohydrates. In: Burtis CA, Ashwood ER, eds. *Tietz Textbook of Clinical Chemistry*. 2nd ed. Philadelphia: W.B. Saunders Company; 1994.
3. Jones AE, Puskarich MA. Sepsis-Induced Tissue Hypoperfusion. *Critical Care Clinics*. October 2009;25(4):769-779.
4. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. *Intensive Care Medicine*. January 2008;34(1):17-60.
5. Shapiro NI, Fisher C, Donnino M, et al. The Feasibility and Accuracy of Point-of-Care Lactate Measurement in Emergency Department Patients with Suspected Infection. *Journal of Emergency Medicine*. July 2010;39(1):89-94.
6. Crowl ACM, Young JSM, Kahler DMM, Claridge JAM, Chrzanowski DSB, Pomphrey MR. Occult Hypoperfusion Is Associated with Increased Morbidity in Patients Undergoing Early Femur Fracture Fixation. *J Trauma*. 2000;48(2):260-267.
7. Paladino L, Sinert R, Wallace D, Anderson T, Yadav K, Zehtabchi S. The utility of base deficit and arterial lactate in differentiating major from minor injury in trauma patients with normal vital signs. *Resuscitation*. June 2008;77(3):363-368.
8. Blow, Osbert MD P, Magliore LB, Claridge JAM, Butler KR, Young JSM. The Golden Hour and the Silver Day: Detection and Correction of occult hypoperfusion within 24 hours improves outcome from major trauma. *Journal of Trauma and Acute Care Surgery*. 1999;47(5):964.
9. Bakker J, De Lima AP. Increased blood lactate levels: An important warning signal in surgical practice
10. Husain FA, Martin MJ, Mullenix PS, Steele SR, Elliott DC. Serum lactate and base deficit as predictors of mortality and morbidity. Paper presented at: American Journal of Surgery, 2003.
11. Rossi AF, Khan DM, Hannan R, Bolivar J, Zaidenweber M, Burke R. Goal-directed medical therapy and point-of-care testing improve outcomes after congenital heart surgery. *Intensive Care Med*. 2005;31(1):98-104.
12. Tietz NW, Pruden EL, Siggard-Andersen O. Electrolytes. In: C.A. Burtis and E.R. Ashwood, ed. *Tietz Textbook of Clinical Chemistry*. Second Edition ed. Philadelphia: W.B. Saunders Company; 1994.
13. CLSI. Blood Gas and pH Analysis and Related Measurements; Approved Guideline. *CLSI document C46-A*. 2001.
14. Young DS. *Effects of Drugs on Clinical Laboratory Tests*. 3rd ed. ed. Washington, DC: American Association of Clinical Chemistry; 1990.
15. Painter PC, Cope JY, Smith JL. Reference Ranges, Table 41–20. In: C.A. Burtis and E.R. Ashwood, ed. *Tietz Textbook of Clinical Chemistry*. Second Edition ed. Philadelphia: W.B. Saunders Company; 1994.
16. Statland BE. *Clinical Decision Levels for Lab Tests*. Oradell, NJ: Medical Economic Books; 1987.

-
17. CLSI. Evaluation of precision performance of clinical chemistry devices : approved guideline. *CLSI document EP5-A*. 1999.
 18. CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline. *CLSI document EP9-A*. 1995.
 19. Cornbleet PJ, Gochman N. Incorrect least-squares regression coefficients in method-comparison analysis. *Clinical Chemistry*. 1979;25(3).
 20. Clinical and Laboratory Standards Institute. Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition. *CLSI document EP7-A2*. 2005.
 21. Wu AHB. *Tietz Clinical Guide to Laboratory Tests*: Elsevier Health Sciences; 2006.
 22. Hankins DC, Kharasch ED. Determination of the halothane metabolites trifluoroacetic acid and bromide in plasma and urine by ion chromatography. *Journal of Chromatography B: Biomedical Applications*. May 1997;692(2):413-418.
 23. Kharasch ED, Hankins D, Mautz D, Thummel KE. Identification of the enzyme responsible for oxidative halothane metabolism: Implications for prevention of halothane hepatitis. *Lancet*. May 1996;347(9012):1367-1371.
 24. Morrison JE, Friesen RH. Elevated serum bromide concentrations following repeated halothane anaesthesia in a child. *Canadian Journal of Anaesthesia*. October 1990;37(7):801-803.
 25. Charles RA, Bee YM, Eng PHK, Goh SY. Point-of-care blood ketone testing: Screening for diabetic ketoacidosis at the emergency department. *Singapore Medical Journal*. November 2007;48(11):986-989.
 26. Morgan TJ, Clark C, Clague A. Artifactual elevation of measured plasma L-lactate concentration in the presence of glycolate. *Crit Care Med*. 1999;27(10):2177-2179.
 27. Porter WH, Crellin M, Rutter PW, Oeltgen P. Interference by Glycolic Acid in the Beckman Synchron Method for Lactate: A Useful Clue for Unsuspected Ethylene Glycol Intoxication. *Clin Chem*. 2000;46(6):874-875.

i-STAT is a trademark of the Abbott Group of companies.

Vacutainer is a registered trademark of Becton Dickinson and Company, Franklin Lakes, NJ USA.

Diprivan is a registered trademark of the AstraZeneca group of companies.

Pentothal Sodium is a registered trademark of Abbott Labs., USA.

Nesdonal Sodium is a registered trademark of Specia, France.

Intraval Sodium is a registered trademark of May and Baker, Ltd., England.

Trapanal is a registered trademark of Chemische Fabrik Promonta, Germany.


Droxia and Hydrea are registered trademarks of Bristol-Myers Squibb Company, Princeton, NJ.

BGE is a registered trademark of Instrumentation Laboratory, Lexington, MA USA.

ICA 1 and ABL are trademark of Radiometer Medical A/S, Copenhagen, Denmark.

Stat Profile is a registered trademark of Nova Biomedical, Waltham, MA USA.

Bayer 845 is manufactured by Bayer Diagnostics (Siemens), Tarrytown, NY USA.



EMERGO EUROPE
Prinsessegracht 20
2514 AP The Hague
The Netherlands



©2019 Abbott Point of Care Inc. All rights reserved. Printed in USA.